JERUSALEM, March 21, 2013 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of voice activated drug safety application announced today that the company is actively initiating a business development plan to commercialize its newly acquired technology.
During the first stage of the business development plan, SafeCode intends to initiate a formal search for market-tested executives to help the company's management team and to raise additional funds to reach its commercialization objectives.
The company recently reported that SafeCode Drug Technologies acquired Quickool and EZJect technology from Sindolor Medical Ltd., an Israel-based medical technologies development company. The breakthrough Quickool technology enabling individuals to self-administer pain free injections.
The technologies enable individuals to safely and painlessly administer injections or blood lancing, by quickly cooling the site of the injection immediately prior to the piercing of the skin. The technology is particularly useful for patients with diabetes who need to test blood-sugar levels or inject themselves regularly with insulin.
Sindolor had previously been in involved in advanced negotiations with a major pharmaceutical company to fully commercialize the painless injection technology.
"The company is extremely optimistic that we can bring our newly acquired pain reduction technologies to market, in addition to the market-tested life-saving technologies that SafeCode already offers," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies. "We are excited by the opportunities this technology presents to our shareholders, and we intend to keep providing updates on our business development activities."
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of patent-pending technologies based on voice recognition for drug safety application.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
|SOURCE Safecode Drug Technologies Corp.|
Copyright©2012 PR Newswire.
All rights reserved